Cell therapy moves into non-malignant rare disease

Cell therapy has been a haematology-and-oncology story until now. Late-stage programs in severe autoimmune disease and inherited metabolic conditions are testing whether the modality extends. The infrastructure question is whether non-malignant indications can use community settings rather than the existing centre-of-excellence network.